Evidence map›Paper›PMID 38836116›Full record

ReviewDrug design, development and therapy2024

Neurovascular Adverse Effects of Sars-Cov-2 Vaccination.

Leonidas D Panos, Panagiotis Bargiotas, Georgios Hadjigeorgiou, Georgios D Panos

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Leonidas D PanosDepartment of Neurology, Bern University Hospital « Inselspital », Bern, Switzerland.
Panagiotis BargiotasDepartment of Neurology, School of Medicine, University of Cyprus, Nicosia, Cyprus.
Georgios HadjigeorgiouDepartment of Neurology, School of Medicine, University of Cyprus, Nicosia, Cyprus.ORCID 0000-0001-5386-4273
Georgios D PanosDepartment of Ophthalmology, Queen's Medical Centre, Nottingham University Hospitals (NUH), Nottingham, U.K.ORCID 0000-0001-8399-7456

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global deployment of SARS-CoV-2 vaccines has been pivotal in curbing the COVID-19 pandemic, reducing morbidity and mortality associated with the virus. While most of these vaccines have demonstrated high efficacy and overall safety, emerging reports have highlighted potential neurovascular adverse effects, albeit uncommon, associated with these vaccinations. This review aims to assess and summarize the current knowledge on the neurovascular complications arising post-SARS-CoV-2 vaccination. We conducted an extensive literature review, focusing on clinical studies and case reports to identify reported neurovascular events, such as ischemic stroke, cerebral sinus venous thrombosis, intracerebral hemorrhage, pituitary apoplexy and primary CNS angiitis Despite the relative rarity of these events, their impact on affected individuals underscores the importance of ongoing surveillance, early detection, and management strategies. We aim to provide healthcare professionals with the latest evidence on neurovascular adverse effects, facilitating informed decision-making in the context of SARS-CoV-2 vaccination programs. Furthermore, we highlight areas requiring further research to understand the pathophysiology of these adverse events better and to develop targeted prevention and treatment strategies.

Indexed as

COVID-19COVID-19 VaccinesHumansSARS-CoV-2VaccinationCOVID-19 VaccinesBNT162b2ChAdOx1coronavirusCOVID-19mRNA-1273neurovascular adverse effectsNVX-CoV2373pandemicSARS-CoV-2vaccines

Identifiers

PMID38836116
PMCPMC11147783

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.